Incyte Reports Q3 Loss of $784.8M on Increased R&D; Revenue Rises to $1.56B

Incyte Corporation reported a significant net loss of $784.8 million for the third quarter of 2026, a sharp contrast to the net income of $424.2 million in the same period last year. This downturn was primarily driven by a substantial increase in research and development expenses, including the acquisition of Vega Therapeutics for $1.25 billion, which resulted in a $1.232 billion R&D charge. Despite the net loss, total revenues saw a healthy increase to $1.56 billion, up from $1.37 billion year-over-year, with notable growth in net sales for key products like JAKAFI and OPZELURA. The company ended the quarter with a strong cash position of $3.28 billion.